News

The agreement resolves litigation that was pending in the US District Court of Texas with respect to certain CR Bard products. The technology generally relates to surgical devices

The company expects to begin Phase III clinical trials at multiple sites across the US in the second quarter of 2009. As part of this investigational new drug

Deni Zodda, the company’s chief business officer, has been appointed interim CFO and corporate secretary. The company has also hired Joseph Warusz as a consultant, who will serve

Boehringer Ingelheim has reported that the last patient has completed treatment in the Phase III randomized evaluation of long term anticoagulant therapy study. This randomized evaluation of long

According to NeuroVasx, the cPAX system is a minimally invasive device for the embolization of cerebral aneurysms, abnormal bulges or sacs in the wall of an artery in

Delcath Systems, a medical technology company, has reported that the data and safety monitoring board has unanimously recommended continuation of the company’s Phase III clinical trial for inoperable

Successful completion of this offer would raise the stake of Novartis in its Indian subsidiary to nearly 90% from the current level of 50.9%. The offer represents a

The exclusive agreement is worldwide in scope, with the exception of certain Asian markets, and covers all major dermatological conditions, excluding onychomycosis and orphan drug indications. Under the

The company has requested a priority review of the application, which, if granted, would give the FDA six months from receipt of the submission to take action on